Hemogenyx Pharmaceuticals (LON:HEMO) Hits New 52-Week High - Time to Buy?

Hemogenyx Pharmaceuticals Plc (LON:HEMO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 410 ($5.17) and last traded at GBX 400.50 ($5.05), with a volume of 102058 shares changing hands. The stock had previously closed at GBX 1.08 ($0.01).

Hemogenyx Pharmaceuticals Stock Down 2.3 %

The firm has a market capitalization of £5.63 billion, a P/E ratio of -42,000.00 and a beta of 3.14. The company's fifty day simple moving average is GBX 9.61 and its 200 day simple moving average is GBX 4.24. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 92.09.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.